miR-155 regulates the proliferation and invasion of clear cell renal cell carcinoma cells by targeting E2F2
暂无分享,去创建一个
Xin Ma | Lei Wang | Xu Zhang | Yu Gao | Zhengwei Lei | Yu Zhang | Yang Fan | Hong-zhao Li | Xin Ma | Yu Gao | Yu Zhang | Xu Zhang | Hongzhao Li | Yuanxin Yao | Chaofei Zhao | Minghui Ma | Lei Wang | Yang Fan | Yuanxin Yao | Minghui Ma | Chaofei Zhao | Z. Lei
[1] Zhiwen Xu,et al. The network of microRNAs, transcription factors, target genes and host genes in human renal cell carcinoma , 2014, Oncology letters.
[2] Ryan M. O’Connell,et al. miR-155-SOCS1 as a Functional Axis: Satisfying the Burden of Proof. , 2015, Immunity.
[3] V. Khoo,et al. Radiotherapy for renal-cell carcinoma. , 2014, The Lancet. Oncology.
[4] A. Jemal,et al. Cancer statistics, 2013 , 2013, CA: a cancer journal for clinicians.
[5] N. Dubrawsky. Cancer statistics , 1989, CA: a cancer journal for clinicians.
[6] Jean-Jacques Patard,et al. EAU guidelines on renal cell carcinoma: the 2010 update. , 2010, European urology.
[7] G. Bhanot,et al. Identification of a microRNA panel for clear-cell kidney cancer. , 2010, Urology.
[8] Xin Ma,et al. Overexpression of E2F1 Promotes Tumor Malignancy And Correlates with TNM Stages in Clear Cell Renal Cell Carcinoma , 2013, PloS one.
[9] Nidhi Sharma,et al. Cell proliferation in the absence of E2F1-3. , 2011, Developmental biology.
[10] W. Krek,et al. Integrated genomic analysis identifies subclasses and prognosis signatures of kidney cancer , 2015, Oncotarget.
[11] M. Malumbres,et al. E2F2 represses cell cycle regulators to maintain quiescence , 2008, Cell cycle.
[12] T. Litman,et al. STAT5-mediated expression of oncogenic miR-155 in cutaneous T-cell lymphoma , 2013, Cell cycle.
[13] Tianxin Lin,et al. MicroRNA-155 promotes bladder cancer growth by repressing the tumor suppressor DMTF1 , 2015, Oncotarget.
[14] You-cai Zhao,et al. MicroRNA expression profiles predict clinical phenotypes and prognosis in chromophobe renal cell carcinoma , 2015, Scientific Reports.
[15] Xing-Sui Lu,et al. miR-141 Is a Key Regulator of Renal Cell Carcinoma Proliferation and Metastasis by Controlling EphA2 Expression , 2014, Clinical Cancer Research.
[16] V. Ambros,et al. Role of MicroRNAs in Plant and Animal Development , 2003, Science.
[17] Suzanne D Turner,et al. Oncogenic role of miR-155 in anaplastic large cell lymphoma lacking the t(2;5) translocation , 2015, The Journal of pathology.
[18] Hong-bing Chen,et al. Investigation of microRNA-155 as a serum diagnostic and prognostic biomarker for colorectal cancer , 2015, Tumor Biology.
[19] Xiangjun Lyu,et al. Hypoxia-induced overexpression of stanniocalcin-1 is associated with the metastasis of early stage clear cell renal cell carcinoma , 2015, Journal of Translational Medicine.
[20] E2f1, E2f2, and E2f3 Control E2F Target Expression and Cellular Proliferation via a p53-Dependent Negative Feedback Loop , 2012, Molecular and Cellular Biology.
[21] G. Luo,et al. miR-106b-5p targets tumor suppressor gene SETD2 to inactive its function in clear cell renal cell carcinoma , 2015, Oncotarget.
[22] David S. Park,et al. Unique Requirement for Rb/E2F3 in Neuronal Migration: Evidence for Cell Cycle-Independent Functions , 2007, Molecular and Cellular Biology.
[23] F. Christians,et al. E2Fs regulate the expression of genes involved in differentiation, development, proliferation, and apoptosis. , 2001, Genes & development.
[24] Xiaokun Zhao,et al. microRNA-155 silencing inhibits proliferation and migration and induces apoptosis by upregulating BACH1 in renal cancer cells , 2012, Molecular medicine reports.
[25] M. Seto,et al. Genome‐wide microRNA expression profiling in renal cell carcinoma: significant down‐regulation of miR‐141 and miR‐200c , 2008, The Journal of pathology.
[26] L. Naldini,et al. A role for miR-155 in enabling tumor-infiltrating innate immune cells to mount effective antitumor responses in mice. , 2013, Blood.
[27] Hans Lehrach,et al. MicroRNA profiling of clear cell renal cell cancer identifies a robust signature to define renal malignancy , 2009, Journal of cellular and molecular medicine.
[28] N. Concin,et al. Expression of the E2F Family of Transcription Factors and Its Clinical Relevance in Ovarian Cancer , 2006, Annals of the New York Academy of Sciences.
[29] D. Raggi,et al. Clinical experience with temsirolimus in the treatment of advanced renal cell carcinoma , 2015, Therapeutic Advances in Urology.
[30] Xiao Han,et al. Up-regulated miR-155-5p promotes cell proliferation, invasion and metastasis in colorectal carcinoma. , 2015, International journal of clinical and experimental pathology.
[31] T. Choueiri,et al. Efficacy of targeted therapies after PD-1/PD-L1 blockade in metastatic renal cell carcinoma. , 2015, European journal of cancer.
[32] Yurong Fu,et al. Differential expression of miRNA patterns in renal cell carcinoma and nontumorous tissues , 2010, Journal of Cancer Research and Clinical Oncology.
[33] D. Bartel. MicroRNAs Genomics, Biogenesis, Mechanism, and Function , 2004, Cell.
[34] Yiliang Zhang,et al. Hepatitis C virus‐induced up‐regulation of microRNA‐155 promotes hepatocarcinogenesis by activating Wnt signaling , 2012, Hepatology.
[35] J. DeGregori,et al. The genetics of the E2F family of transcription factors: shared functions and unique roles. , 2002, Biochimica et biophysica acta.
[36] Jian Gao,et al. TGF-β1 acts through miR-155 to down-regulate TP53INP1 in promoting epithelial-mesenchymal transition and cancer stem cell phenotypes. , 2015, Cancer letters.
[37] S. Oudard,et al. The role of rechallenge with targeted therapies in metastatic renal-cell carcinoma , 2015, Current opinion in urology.
[38] N. Dyson,et al. The E2F transcriptional network: old acquaintances with new faces , 2005, Oncogene.
[39] T. Sellers,et al. Upregulation of miRNA-155 promotes tumour angiogenesis by targeting VHL and is associated with poor prognosis and triple-negative breast cancer , 2013, Oncogene.
[40] H. Mankin,et al. MicroRNA-155 expression is independently predictive of outcome in chordoma , 2015, Oncotarget.
[41] Tao Xi,et al. miR-155 regulates the proliferation and cell cycle of colorectal carcinoma cells by targeting E2F2 , 2014, Biotechnology Letters.
[42] Shuai Jiang,et al. MicroRNA-155 functions as an OncomiR in breast cancer by targeting the suppressor of cytokine signaling 1 gene. , 2010, Cancer research.
[43] I. Ernberg,et al. Inhibition of MiR-155 suppresses cell migration in nasopharyngeal carcinoma through targeting ZDHHC2. , 2015, International journal of clinical and experimental medicine.
[44] Hong-zhao Li,et al. MicroRNA-185 inhibits cell proliferation and induces cell apoptosis by targeting VEGFA directly in von Hippel-Lindau-inactivated clear cell renal cell carcinoma. , 2015, Urologic oncology.
[45] Umberto Capitanio,et al. Renal Cancer , 2011 .
[46] B. Escudier,et al. mTOR-inhibitor treatment of metastatic renal cell carcinoma: contribution of Choi and modified Choi criteria assessed in 2D or 3D to evaluate tumor response , 2015, European Radiology.
[47] N. A. Walton,et al. Specific tumor suppressor function for E2F2 in Myc-induced T cell lymphomagenesis , 2007, Proceedings of the National Academy of Sciences.